Idenix takes to Europe with its Gilead patent spat

Idenix Pharmaceuticals ($IDIX) believes Gilead Sciences ($GILD) violated its patents with the blockbuster-selling hepatitis C pill Sovaldi, and the biotech has expanded its legal fight into Europe, angling for a cut of sales. In lawsuits filed in France, Germany and the U.K., Idenix claims Gilead stepped on its intellectual property related to nucleoside treatments for hep C, following a similar legal effort launched in the U.S. in December. More

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.